Adult leukemia and myeloma treatment and immune-safety center
Adult Leukemia Research Center
Trying new ways to make immune-cell therapies safer and better at preventing relapse for adults with acute leukemias or multiple myeloma.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11177691 on NIH RePORTER |
What this research studies
From a patient perspective, this program studies immune-based treatments such as CAR T cells and T cell receptor therapies and how they work after stem cell transplants. Researchers use laboratory and preclinical models that mirror the clinical treatments to learn why infections, graft-versus-host disease (GVHD), and cytokine release syndrome (CRS) happen. The goal is to develop approaches that reduce these toxicities while keeping or improving the anti-leukemia and anti-myeloma effects. Findings are intended to inform clinical projects that could change how these therapies are given to patients.
Who could benefit from this research
Good fit: Adults (21+) with acute myeloid or lymphoid leukemia or relapsed/refractory multiple myeloma, especially those who are candidates for stem cell transplant or CAR T/TCR-based therapies.
Not a fit: Children, people without leukemia or myeloma, and patients not eligible for or interested in immune-cell or transplant therapies are unlikely to benefit directly.
Why it matters
Potential benefit: Could lead to safer, more durable immune-cell therapies that reduce relapse and treatment complications for adults with AML, ALL, or multiple myeloma.
How similar studies have performed: CAR T cell and transplant-related T cell therapies have produced strong remissions in many patients but relapse and immune toxicities remain common, so this work builds on promising yet incomplete successes.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Hill, Geoffrey Roger — Fred Hutchinson Cancer Center
- Study coordinator: Hill, Geoffrey Roger
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.